Strategic Acquisition Spinal Modulation was acquired by St. Jude Medical, indicating potential access to larger distribution networks, sales channels, and post-market support infrastructure that can be leveraged for broader market penetration and cross-selling of neuromodulation solutions.

Global Footprint With operations in the United States, Europe, and Australia, there are opportunities to coordinate multinational sales campaigns, expand reimbursement discussions, and tailor region-specific value propositions to drive adoption of the Axium system.

Clinical Evidence The ACCURATE study and the global use of Axium in pain centers provide a clinical foundation to support sales pitches, highlight real-world efficacy for dorsal root ganglion stimulation, and address payer and clinician demand for robust trial data.

Growth Readiness Private equity and venture-backed funding indicate strong investor interest, suggesting potential for strategic partnerships, co-development opportunities, or accelerated clinical trials to expand indications and strengthen market position.

Revenue Leveragability Existing revenue range and large potential market in neurostimulation, combined with St. Jude Medical’s distribution network, create opportunities for bundled offerings, service contracts, and integration with complementary neuromodulation devices to drive higher lifetime value.